Monograph Details
|
|
Infections & Infestations
> Fungal infections
|
|
MYCAMINE |
| Manufacturer |
|
Astellas Pharma US, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Glucan synthesis inhibitor/echinocandin. |
| Generic Name |
|
Micafungin sodium 50mg/vial, 100mg/vial; pwd for IV infusion after reconstitution and dilution; preservative-free. |
| Indications |
|
Treatment of Candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses; and esophageal candidiasis. Prophylaxis of Candida infection in patients undergoing hematopoietic stem cell transplantation (HSCT). |
| Children |
|
Not recommended. |
| Adults |
|
Give by slow IV infusion over 1 hour. Candidemia, acute disseminated, peritonitis, abscesses: 100mg/day (usual range 10–47 days). Esophageal: 150mg/day (usual range 10–30 days). Prophylaxis in HSCT: 50mg/day (usual range 6–51 days). |
| Precautions |
|
Severe hepatic impairment. Renal dysfunction. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Potentiates sirolimus, itraconazole, nifedipine (monitor). |
| Adverse Reactions |
|
Inj site reactions, GI upset, fever, headache, flushing, phlebitis, rash, blood dyscrasias, increased alkaline phosphatase, abnormal liver function tests (eg, ALT/AST), anaphylaxis. |
| How Supplied |
|
Single-use vials—10 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
